Neogen Corporation $NEOG Stock Holdings Decreased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its position in shares of Neogen Corporation (NASDAQ:NEOG) by 3.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,246,638 shares of the company’s stock after selling 47,640 shares during the quarter. Bank of New York Mellon Corp owned 0.57% of Neogen worth $11,581,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NEOG. UMB Bank n.a. raised its position in Neogen by 238.2% during the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after buying an additional 4,523 shares during the period. Hantz Financial Services Inc. boosted its position in Neogen by 816.9% during the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after acquiring an additional 6,764 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Neogen by 3,158.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock valued at $58,000 after acquiring an additional 8,054 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Neogen in the 4th quarter valued at about $65,000. Finally, Merit Financial Group LLC purchased a new stake in shares of Neogen in the fourth quarter worth approximately $71,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Neogen Stock Up 4.4%

NEOG stock opened at $12.04 on Friday. Neogen Corporation has a 1 year low of $4.56 and a 1 year high of $12.15. The company has a fifty day simple moving average of $9.44 and a 200 day simple moving average of $9.62. The firm has a market cap of $2.62 billion, a PE ratio of -401.33, a PEG ratio of 5.16 and a beta of 1.80. The company has a current ratio of 3.82, a quick ratio of 2.84 and a debt-to-equity ratio of 0.38.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The business had revenue of $225.30 million for the quarter, compared to analyst estimates of $212.35 million. During the same quarter in the prior year, the firm posted ($2.82) EPS. The firm’s revenue for the quarter was down .1% on a year-over-year basis. Sell-side analysts anticipate that Neogen Corporation will post 0.22 EPS for the current fiscal year.

Key Stories Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Neogen reported fiscal Q4 adjusted earnings of $0.09 per share, above the $0.05 analyst consensus and substantially better than the $2.82-per-share loss reported in the year-ago quarter. Revenue of $225.3 million also exceeded estimates of $212.35 million. Neogen Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Management forecast fiscal 2027 revenue of $880 million to $885 million, above the $851.1 million consensus estimate. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. Neogen Fiscal 2027 Guidance
• Positive Sentiment: The company expects fiscal 2027 adjusted EBITDA of approximately $180 million to $182 million, signaling anticipated improvement in profitability and supporting the favorable investor reaction. Neogen Fiscal 2026 Results
• Neutral Sentiment: Despite the earnings beat, quarterly revenue was essentially flat year over year, down 0.1%, indicating that the stronger outlook depends on future growth rather than current top-line acceleration.
• Neutral Sentiment: Analysts’ average price target is approximately $10.67, below the stock’s recent trading level, suggesting valuation and expectations may limit additional upside. Analysts Set Neogen Price Target
• Negative Sentiment: Neogen plans to increase research and development spending by roughly 50% in fiscal 2027. Although intended to support longer-term growth, the investment could pressure near-term margins and earnings.

Analysts Set New Price Targets

A number of research analysts recently commented on NEOG shares. Wall Street Zen raised shares of Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded shares of Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.67.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.